Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Learn more about:
Related Clinical Trial
A Study of IMU-201 (PD1-Vaxx), a B-Cell Immunotherapy, in Adults With Non-Small Cell Lung Cancer Adherence to Survivorship Care Guidelines in Health Care Providers for Non-Small Cell Lung Cancer and Colorectal Cancer Survivor Care Docetaxel With Either Cetuximab or Bortezomib as First-Line Therapy in Treating Patients With Stage III or Stage IV Non-Small Cell Lung Cancer Icotinib for Completed Resected IB NSCLC With EGFR Mutation Circulating Tumor DNA in Patients at High Risk for Lung Cancer Gefitinib in Treating Patients With Stage IB, II, or IIIA Non-small Cell Lung Cancer That Was Completely Removed by Surgery Combination Chemotherapy, Radiation Therapy, and Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer Study of Ponatinib in Patients With Lung Cancer Preselected Using Different Candidate Predictive Biomarkers Radiation Therapy, Chemotherapy, and Soy Isoflavones in Treating Patients With Stage IIIA-IIIB Non-Small Cell Lung Cancer Docetaxel, Cisplatin, Pegfilgrastim, and Erlotinib Hydrochloride in Treating Patients With Stage IIIB or Stage IV Non-Small Cell Lung Cancer S0536: Cetuximab, Paclitaxel, Carboplatin, and Bevacizumab in Treating Patients With Advanced Non-Small Cell Lung Cancer Erlotinib and Radiation Therapy Plus Combination Chemotherapy in Treating Patients With Inoperable Stage III Non-Small Cell Lung Cancer Combination Chemotherapy With or Without Bevacizumab in Treating Patients With Advanced, Metastatic, or Recurrent Non-Small Cell Lung Cancer Combination Chemotherapy and Radiation Therapy With or Without Gefitinib in Treating Patients With Stage III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Surgery With or Without Chemotherapy in Treating Patients With Stage I Non-small Cell Lung Cancer Phase I IGART Study Using Active Breathing Control and Simultaneous Boost for Patients With NSCLC Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery Bevacizumab, Paclitaxel, Carboplatin, and Radiation Therapy to the Chest in Treating Patients With Locally Advanced Non-Small Cell Lung Cancer Bortezomib in Treating Patients With Stage IIIB or Stage IV Lung Cancer S0341: Erlotinib in Treating Patients With Advanced Primary Non-Small Cell Lung Cancer Combination Chemotherapy Plus Radiation Therapy With or Without AE-941 in Treating Patients With Stage III Non-small Cell Lung Cancer That Cannot Be Removed By Surgery QUILT-3.017: Study of NEO-201 in Solid Tumors Photodynamic Therapy in Treating Patients With Lung Cancer Vaccine Treatment for Advanced Non-Small Cell Lung Cancer S1300: Pemetrexed Disodium With or Without Crizotinib in Treating Patients With Stage IV Non-Small Cell Lung Cancer That Has Progressed After Crizotinib Single Agent Chemotherapy +/- Nivolumab in Patients With Advanced Squamous or Non-squamous NSCLC With Primary Resistance to Prior PD-1 or PDL-1 Inhibitor Comparison of Different Types of Surgery in Treating Patients With Early-stage Non-small Cell Lung Cancer Therapeutic ResistAnce and Clonal Evolution Assessed With Liquid Biopsy of NSCLC Patients in China ALK/ROS1/MET Mutations on Plasma ctDNA in Patients With NSCLC The Tracking Molecular Evolution for NSCLC (T-MENC) Study Phase 1a/1b Study of TPST-1495 Alone and With Pembrolizumab in Subjects With Solid Tumors An Integrated Approach to Treating Recurrent Thoracic Carcinomas Resistant to Tyrosine Kinase Inhibitors Low-Dose Acetylsalicylic Acid in Treating Patients With Stage I-III Non-Small Cell Lung Cancer LMB-100 Followed by Pembrolizumab in the Treatment of Adults With Mesothelin-Expressing Non-Squamous Non-Small Cell Lung Cancer (NSCLC) P2 of RMT in Combo w Durvalumab or Durva + Chemo in Untreated Adenocarcinoma NSCLC Feasibility and Safety of Nintedanib in Combination With Nivolumab in Pretreated Patients With Advanced or Metastatic NSCLC of Adenocarcinoma Histology Targeted Stem Cells Expressing TRAIL as a Therapy for Lung Cancer Combination Nab-paclitaxel (N-P) and Nintedanib or N-P and Placebo in Relapsed NSCLC Adenocarcinoma Prospective Radiological Study of HRCT to Predict Pathological Noninvasiveness in NSCLC To Compare Efficacy and Safety of CT-P16 and EU-Approved Avastin as First-Line Treatment for Metastatic or Recurrent Non-Squamous Non-Small Cell Lung Cancer Hsp90 Inhibitor AUY922 and Erlotinib Hydrochloride in Treating Patients With Stage IIIB-IV Non-Small Cell Lung Cancer Impact of Concomitant Genetic Alterations in EGFR Mutated Adenocarcinoma by NGS Analysis: A Multicenter Study Bemcentinib (BGB324) in Combination With Pembrolizumab in Patients With Advanced NSCLC Poziotinib in Stage IV Lung Adenocarcinoma With HER2 Mutation (KASTT001) Study of Nivolumab in Combination With GM.CD40L Vaccine in Adenocarcinoma of the Lung Study of AXL1717 Compared to Docetaxel to Treat Squamous Cell Carcinoma or Adenocarcinoma of the Lung Lung Cancer Mutation Consortium Protocol The Detection of EGFR Mutations in Liquid Based Cytology Samples NOV120101 (Poziotinib) for 1st Line Monotherapy in Patients With Lung Adenocarcinoma A Safety and Efficacy Study of Farletuzumab in Subjects With Adenocarcinoma of the Lung Study of Vintafolide (MK-8109, EC145) in Participants With Progressive Adenocarcinoma of the Lung (MK-8109-008, EC-FV-03) Endostar Durative Transfusion Combined With Chemotherapy in the Treatment of Advanced Lung Adenocarcinoma The Study of Apatinib Plus CIK as the Third Line Therapy for Advanced Lung Adenocarcinoma Patients With Wild-Type EGFR Telomere Biology in Early Adenocarcinoma of the Lung

Brief Title

Image-Guided Hypofractionated Radiation Therapy With Stereotactic Body Radiation Therapy Boost and Combination Chemotherapy in Treating Patients With Stage II-III Non-Small Cell Lung Cancer That Cannot Be Removed By Surgery

Official Title

Image-Guided Hypofractionated Radiotherapy With Stereotactic Boost and Chemotherapy for Inoperable Stage II-III Non-Small Cell Lung Cancer

Brief Summary

      This clinical trial studies image-guided hypofractionated radiation therapy (RT) when given
      together with hypofractionated RT boost and combination chemotherapy in treating patients
      with stage II-III non-small cell lung cancer (NSCLC) that cannot be removed by surgery. RT
      uses high energy x-rays to kill tumor cells. Hypofractionated RT may be able to send x-rays
      directly to the tumor and cause less damage to normal tissue. Drugs used in chemotherapy,
      such as carboplatin and paclitaxel, work in different ways to stop the growth of tumor cells,
      either by killing the cells or by stopping them from dividing. Giving RT together with
      combination chemotherapy may kill more tumor cells and allow doctors to save the part of the
      body where the cancer started
    

Detailed Description

      PRIMARY OBJECTIVES:

      I. To determine the maximum tolerated dose (MTD) using hypofractionated RT in patients with
      stage II-III NSCLC.

      SECONDARY OBJECTIVES:

      I. To determine the dose-limiting toxicity, if the MTD is reached.

      II. To determine the tumor local control (LC).

      III. To determine the lung cancer disease specific survival (DSS).

      IV. To determine the overall survival (OS).

      V. To assess the transforming growth factor-beta (TGF-B), interleukin (IL)-1, and IL-6 levels
      as predictive biomarkers for treatment induced tissue injury.

      OUTLINE: This is a dose-escalation study of image-guided hypofractionated RT.

      Patients undergo image-guided hypofractionated RT over 35 minutes 5 days a week for 2 weeks
      followed by 5 fractions of hypofractionated RT boost. Patients also receive standard
      carboplatin and paclitaxel for 3 weeks.

      After completion of study treatment, patients are followed up at 4-6 weeks, every 3 months
      for the first 2 years, and then periodically thereafter.
    


Study Type

Interventional


Primary Outcome

To determine the maximal tolerated dose using hypofractionated radiotherapy in patients with stage II-III non small cell lung cancer.

Secondary Outcome

 To determine tumor Local control

Condition

Adenocarcinoma of the Lung

Intervention

hypofractionated radiation therapy

Study Arms / Comparison Groups

 Treatment (dose-escalation of RT)
Description:  Patients undergo image-guided hypofractionated RT over 35 minutes 5 days a week for 2 weeks followed by 5 fractions of hypofractionated RT boost. Patients also receive standard carboplatin and paclitaxel for 3 weeks.

Publications

* Includes publications given by the data provider as well as publications identified by National Clinical Trials Identifier (NCT ID) in Medline.

Recruitment Information


Recruitment Status

Radiation

Estimated Enrollment

29

Start Date

March 23, 2011

Completion Date

May 1, 2021

Primary Completion Date

December 31, 2020

Eligibility Criteria

        Inclusion Criteria:

          -  Histologically confirmed primary non-metastatic NSCLC; eligible histological subtypes
             include: squamous cell carcinoma, adenocarcinoma, squamous-adeno carcinoma, large-cell
             carcinoma, and non-small cell carcinoma not otherwise specified

          -  Clinical stage II and III NSCLC as defined by American Joint Committee on Cancer
             (AJCC) Cancer Staging Manual, seventh edition; acceptable imaging modalities to
             document nodal positivity include computed tomography (CT) chest, positron emission
             tomography (PET)-CT, or thoracic magnetic resonance imaging (MRI)

          -  For clinically stage II patients, the patient must have been evaluated by a thoracic
             surgeon, and deemed medically or technically inoperable, or the patient must refuse
             surgery

          -  Karnofsky performance status >= 70

          -  If a woman is of childbearing potential, a negative serum pregnancy test must be
             documented; women of childbearing potential must agree to use adequate contraception
             (hormonal or barrier method of birth control; or abstinence) for duration of study
             treatment and for up to 4 weeks following the study treatment

        Exclusion Criteria:

          -  Patients who have previously received therapeutic radiation therapy to the chest

          -  Active systemic, pulmonary, or pericardial infection

          -  Use of concurrent gemcitabine-based chemotherapy during radiotherapy

          -  Pregnant women, or women of childbearing potential who are sexually active and not
             willing/able to use medically acceptable forms of contraception for the entire study
             period and for up to 4 weeks after the study treatment

          -  Refusal to sign the informed consent

          -  Patients who are participating in a concurrent treatment protocol
      

Gender

All

Ages

18 Years - N/A

Accepts Healthy Volunteers

No

Contacts

Percy Lee, , 

Location Countries

United States

Location Countries

United States

Administrative Informations


NCT ID

NCT01345851

Organization ID

10-001342

Secondary IDs

NCI-2011-00673

Responsible Party

Sponsor

Study Sponsor

Jonsson Comprehensive Cancer Center

Collaborators

 National Cancer Institute (NCI)

Study Sponsor

Percy Lee, Principal Investigator, Jonsson Comprehensive Cancer Center


Verification Date

June 2020